Latest Insider Transactions at Liquidia Corp (LQDA)
This section provides a real-time view of insider transactions for Liquidia Corp (LQDA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Liquidia Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Liquidia Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 28
2024
|
Jason Adair Chief Business Officer |
BUY
Open market or private sale
|
Direct |
459
+0.39%
|
$5,049
$11.31 P/Share
|
|
Oct 18
2024
|
Rajeev Saggar Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,526
-1.22%
|
$27,786
$11.19 P/Share
|
|
Oct 14
2024
|
Scott Moomaw Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,527
-0.99%
|
$16,797
$11.11 P/Share
|
|
Oct 14
2024
|
Rajeev Saggar Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,260
-1.08%
|
$24,860
$11.11 P/Share
|
|
Oct 14
2024
|
Russell Schundler General Counsel |
SELL
Open market or private sale
|
Direct |
2,576
-0.53%
|
$28,336
$11.11 P/Share
|
|
Oct 14
2024
|
Jason Adair Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,146
-0.96%
|
$12,606
$11.11 P/Share
|
|
Oct 14
2024
|
Roger Jeffs Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
8,053
-0.98%
|
$88,583
$11.11 P/Share
|
|
Oct 14
2024
|
Michael Kaseta CFO and COO |
SELL
Open market or private sale
|
Direct |
3,892
-1.24%
|
$42,812
$11.11 P/Share
|
|
Oct 11
2024
|
Jason Adair Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,906
+3.16%
|
-
|
|
Sep 12
2024
|
Paul B Manning Director |
BUY
Open market or private purchase
|
Indirect |
337,078
+29.23%
|
$2,696,624
$8.9 P/Share
|
|
Sep 12
2024
|
Caligan Partners LP Director |
BUY
Grant, award, or other acquisition
|
Indirect |
1,123,595
+12.16%
|
$8,988,760
$8.9 P/Share
|
|
Sep 03
2024
|
Russell Schundler General Counsel |
SELL
Open market or private sale
|
Direct |
710
-0.15%
|
$6,390
$9.5 P/Share
|
|
Sep 03
2024
|
Jason Adair Chief Business Officer |
SELL
Open market or private sale
|
Direct |
455
-0.39%
|
$4,095
$9.5 P/Share
|
|
Sep 03
2024
|
Michael Kaseta CFO and COO |
SELL
Open market or private sale
|
Direct |
1,079
-0.34%
|
$9,711
$9.5 P/Share
|
|
Sep 03
2024
|
Scott Moomaw Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
546
-0.35%
|
$4,914
$9.5 P/Share
|
|
Aug 30
2024
|
Caligan Partners LP Director |
BUY
Open market or private purchase
|
Indirect |
150,000
+2.1%
|
$1,350,000
$9.51 P/Share
|
|
Aug 30
2024
|
Caligan Partners LP Director |
SELL
Open market or private sale
|
Indirect |
150,000
-2.14%
|
$1,350,000
$9.51 P/Share
|
|
Aug 30
2024
|
Caligan Partners LP Director |
SELL
Other acquisition or disposition
|
Indirect |
3,440,948
-32.97%
|
-
|
|
Aug 30
2024
|
Russell Schundler General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,344
+0.48%
|
-
|
|
Aug 30
2024
|
Jason Adair Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,562
+1.33%
|
-
|
|
Aug 30
2024
|
Michael Kaseta CFO and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,344
+0.74%
|
-
|
|
Aug 30
2024
|
Scott Moomaw Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,875
+1.2%
|
-
|
|
Jul 26
2024
|
Jason Adair Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,833
-1.59%
|
$20,163
$11.44 P/Share
|
|
Jul 19
2024
|
Rajeev Saggar Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,873
-0.89%
|
$20,603
$11.13 P/Share
|
|
Jul 12
2024
|
Scott Moomaw Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,528
-1.0%
|
$18,336
$12.53 P/Share
|
|
Jul 12
2024
|
Roger Jeffs Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
8,053
-0.97%
|
$96,636
$12.53 P/Share
|
|
Jul 12
2024
|
Rajeev Saggar Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,470
-0.69%
|
$17,640
$12.53 P/Share
|
|
Jul 12
2024
|
Russell Schundler General Counsel |
SELL
Open market or private sale
|
Direct |
1,985
-0.41%
|
$23,820
$12.53 P/Share
|
|
Jul 12
2024
|
Jason Adair Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,146
-0.98%
|
$13,752
$12.53 P/Share
|
|
Jul 12
2024
|
Michael Kaseta CFO and COO |
SELL
Open market or private sale
|
Direct |
3,906
-1.23%
|
$46,872
$12.53 P/Share
|
|
Jul 11
2024
|
Jason Adair Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,907
+3.25%
|
-
|
|
Jun 20
2024
|
Katherine Rielly Gauvin Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,359
+50.0%
|
-
|
|
Jun 20
2024
|
Raman Singh Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,359
+50.0%
|
-
|
|
Jun 20
2024
|
Stephen M Bloch Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,359
+50.0%
|
-
|
|
Jun 20
2024
|
Damian De Goa Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,359
+23.02%
|
-
|
|
Jun 20
2024
|
Joanna Horobin Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,359
+50.0%
|
-
|
|
Jun 20
2024
|
David Edward Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,359
+50.0%
|
-
|
|
Jun 20
2024
|
Arthur S Kirsch Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,359
+47.66%
|
-
|
|
Jun 20
2024
|
Paul B Manning Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,359
+6.36%
|
-
|
|
Jun 03
2024
|
Scott Moomaw Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
546
-0.36%
|
$7,644
$14.55 P/Share
|
|
Jun 03
2024
|
Russell Schundler General Counsel |
SELL
Open market or private sale
|
Direct |
710
-0.15%
|
$9,940
$14.55 P/Share
|
|
Jun 03
2024
|
Jason Adair Chief Business Officer |
SELL
Open market or private sale
|
Direct |
455
-0.4%
|
$6,370
$14.55 P/Share
|
|
Jun 03
2024
|
Michael Kaseta CFO and COO |
SELL
Open market or private sale
|
Direct |
1,094
-0.34%
|
$15,316
$14.55 P/Share
|
|
May 31
2024
|
Scott Moomaw Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,875
+1.2%
|
-
|
|
May 31
2024
|
Russell Schundler General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,344
+0.48%
|
-
|
|
May 31
2024
|
Jason Adair Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,563
+1.37%
|
-
|
|
May 31
2024
|
Michael Kaseta CFO and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,344
+0.73%
|
-
|
|
Apr 19
2024
|
Rajeev Saggar Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,649
-0.77%
|
$21,437
$13.68 P/Share
|
|
Apr 12
2024
|
Roger Jeffs Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
8,360
-1.0%
|
$117,040
$14.58 P/Share
|
|
Apr 12
2024
|
Michael Kaseta CFO and COO |
SELL
Open market or private sale
|
Direct |
3,136
-0.99%
|
$43,904
$14.58 P/Share
|